Business Wire

Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments

Share

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of Ultherapy PRIME – a noninvasive treatment that provides a truly personalized and long-lasting* lift of the skin in one session with zero downtime.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240923820281/en/

Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments (Photo: Business Wire)

The Ultherapy PRIME platform is the evolution of Ultherapy®, which has been recognized as the Gold Standard for nonsurgical lifting and skin tightening due to its large body of clinical evidence, well-established mechanism of action (MOA) and high patient satisfaction.1,2,3 Built on a legacy of proven, natural-looking outcomes, Ultherapy PRIME redefines the future of non-invasive skin lifting and tightening by uniquely combining advanced ultrasound technology, vivid real-time imaging and proven results. These advancements promote long-lasting* results paired with healthier-looking skin.1,2,3,4,5

The platform features a modern design with an advanced operating system, delivering 10x faster processing power, elevated ergonomics and seamless workflows for aesthetic health care professionals. Additionally, with a 35% larger screen and brighter, crisp images from all angles, Ultherapy PRIME offers a vivid visualization experience for a truly personalized, long-lasting* lift patients can see.**

“The launch of Ultherapy PRIME demonstrates our commitment to persist in innovation,” said Bob Rhatigan, CEO, Merz Aesthetics. “As the leader in noninvasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform and as a proven technology*** and customizable, long-lasting* treatment option.”

Ultherapy PRIME’s unique technology with real-time visualization goes beyond other noninvasive treatments to target the right collagen and elastin-rich layers of the tissue at multiple depths, delivering consistent and precise energy where the patient needs it the most.1,2,3,4,6,7 Ultherapy PRIME’s mechanism of action allows for personalized skin lifting outcomes through collagen and elastin stimulation, which can last up to a year or more.1,2,3,4,6,7 It is a great treatment option for all skin types and skin tones to maintain a youthful, healthy appearance in just one session with zero downtime.1

With three million Ultherapy treatments performed around the world, Ultherapy PRIME builds on an impressive legacy of lifts of the skin on the brows, area under the chin and neck and improves lines and wrinkles on the décolleté.1,2,3 With Ultherapy’s 95% patient satisfaction at year one and one of the strongest clinical bodies of evidence cited in over 120 publications and 56 clinical studies,2,4 Ultherapy PRIME is built on a legacy of safe and effective treatments. Ultherapy PRIME is The Lift You Can SEE.

“Now more than ever, patients seek treatments tailored to their unique skin needs. This is why Ultherapy is a cornerstone of my practice,” said world-renowned, board-certified dermatologist Sabrina Fabi, MD. “The new Ultherapy PRIME platform offers all the signature benefits of Ultherapy for noninvasive, long-lasting* lifting, now with significant advancements. Ultherapy PRIME improves the quality of the skin, catering to diverse patient needs with all skin types seeking a noninvasive lift and a younger, healthier appearance in just one session and no downtime.”

To learn more about Ultherapy PRIME, visit Ultherapy.com and follow @Ultherapy on Instagram.

*results can last up to a year or more 1,4
** in comparison to the previous version
***based on clinical studies conducted with Ultherapy legacy device

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

About Ultherapy®:

The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.

References:

  1. Ulthera® Instructions for Use
  2. Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
  3. Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel’s Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79.
  4. Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
  5. Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
  6. Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting.
  7. White WM, Makin IR, Barthe PG, Slayton MN, Gliklich RE. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy: a new target for non-invasive facial rejuvenation. Arch Facial Plast Surg. 2007;9(1):22-29.

© 2024 Merz North America, Inc., Merz, and Merz Aesthetics are trademarks or registered trademarks of Merz Pharma GmbH & Co. KGaA in the EU and/or certain other countries. Ultherapy, Ulthera are trademarks and/or registered trademarks of Ulthera, Inc. in the EU and/or certain other countries. Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and International patents to which Ulthera, Inc. has rights are issued, published, or pending.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240923820281/en/

Contacts

Emily Browder
Head of Global Communications
6501 Six Forks Road Raleigh NC 27615
919-302-3296
media@merz.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 13:00:00 CET | Press Release

Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower cost in payments, so with the support of Visa, we are evaluating how this technology could fit into our broader strategy to deliver meaningful value to ou

SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release

SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ

Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press Release

Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder of Safe Software. “We’re proud to help organizations integrate data seamlessl

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c

BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande

Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye